Table 2 Comparisons of gender, age and cancer rates between BAP1 -mutated and non-mutated cohorts
From: BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs
Variable | BAP1-mutated N=63* | BAP1-non-mutated N=55 | p-value | OR (95%CI) |
|---|---|---|---|---|
Gender | ||||
Male | 22 (36.7%) | 31 (56.4%) | ||
Female | 38 (63.3%) | 24 (43.6%) | 0.034 | - |
Age of follow-up | ||||
Number known | 46 | 42 | ||
Mean age (Std. Err.) | 53.2 (2.1) | 51.0 (2.3) | 0.4851 | - |
At least 1 cancer | ||||
Yes | 40 (63.5%) | 5 (9.1%) | 17.39 | |
No | 23 (36.5%) | 50 (90.9%) | <0.001 | (6.07-49.83) |
Malignant mesothelioma | ||||
Yes | 13 (21.0%) | 0 (0.0%) | ||
No | 49 (79.0%) | 55 (100%) | <0.001 | - |
Uveal melanoma | ||||
Yes | 11 (17.7%) | 0 (0.0%) | ||
No | 51 (82.3%) | 55 (100%) | 0.001 | - |
Cutaneous melanoma | ||||
Yes | 8 (12.9%) | 0 (0.0%) | ||
No | 54 (87.1%) | 55 (100%) | 0.007§ | - |
MBAITs** | ||||
Yes | 24 (66.7%) | 0 (0.0%) | ||
No | 12 (33.3%) | 12 (100%) | <0.001 | - |
Lung cancer | ||||
Yes | 3 (4.8%) | 0 (0.0%) | ||
No | 59 (95.2%) | 55 (100%) | 0.246§ | - |
Breast cancer*** | ||||
Yes | 3 (7.9%) | 1 (4.1%) | ||
No | 35 (91.9%) | 23 (95.9%) | 0.621§ | - |
Renal cancer | ||||
Yes | 2 (3.3%) | 0 (0.0%) | ||
No | 60 (96.7%) | 55 (100%) | 0.497§ | - |